FIA
PTGX icon

FNY Investment Advisers’s Protagonist Therapeutics PTGX Stock Holding History

FNY Investment Advisers’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-500
Closed -$27K – 1457
2025
Q2 		$27K Buy
+500
New +$24K 0.01% 519
2025
Q1 		– Sell
-1,000
Closed -$38K – 927
2024
Q4 		$38K Buy
+1,000
New +$43.6K 0.02% 363
2018
Q4 		– Sell
-3,000
Closed -$30K – 959
2018
Q3 		$30K Buy
3,000
+500
+20% +$4.3K 0.01% 415
2018
Q2 		$16K Buy
+2,500
New +$19.2K 0.01% 386

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

FNY Investment Advisers's PTGX Position: Q3 2025 in Review

FNY Investment Advisers sold out of Protagonist Therapeutics (PTGX) in Q3 2025, closing a stake of 500 shares — an estimated $27K sold.

FNY Investment Advisers first reported a position in PTGX in Q2 2018 and held it in 4 quarters. The position peaked at $38K in Q4 2024. 275 funds tracked by Wall St. Rank hold PTGX as of Q3 2025.

  • FNY Investment Advisers reported no remaining Protagonist Therapeutics position as of Q3 2025 after selling out during the quarter.
  • FNY Investment Advisers sold 500 Protagonist Therapeutics shares in Q3 2025, an estimated $27K.
  • FNY Investment Advisers first reported a position in Protagonist Therapeutics in Q2 2018 and held it in 4 quarters.
  • FNY Investment Advisers's Protagonist Therapeutics position peaked at $38K in Q4 2024.
  • 275 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2025.

Based on FNY Investment Advisers's 13F filing for Q3 2025, filed 15 Dec 2025.